PharmaCyte Biotech's Partner Austrianova Opens New Facilities in Singapore

SILVER SPRING, Md., Jan. 29, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box(R), announced today that its partner, Austrianova, has officially opened its new facilities at Synapse within Biopolis in Singapore. Biopolis is a world-class biomedical sciences hub where key research organizations and institutes are located from around the globe. An "open house" event for guests to visit the new facilities in Singapore was held on January 29, 2015. The Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, attended the opening ceremonies.

Read more...

PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation

SILVER SPRING, Md., Jan. 26, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box(R), today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box(R) capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.

Read more...

PharmaCyte Biotech’s Pancreatic Cancer Treatment Named as Near-Term Approach to Rising Pancreatic Cancer Rates

SILVER SPRING, MD, January 15, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an article naming PharmaCyte Biotech's pancreatic cancer treatment as a near-term approach to tackling the rising pancreatic cancer rates.

Read more...

PharmaCyte Biotech Announces Update on Corporate Changes

Company Trading Under New Ticker Symbol PMCB

SILVER SPRING, MD, January 8, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today announced that the Company is trading under its new ticker symbol "PMCB" effective today. It also announced that PharmaCyte Biotech's CUSIP number has been changed to 71715X104.

Read more...

Nuvilex Announces Name Change to PharmaCyte Biotech

Company's Shares Will Trade Under New Ticker Symbol PHCB

SILVER SPRING, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (PMCB) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol "PHCB" on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change is part of the Company's transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box(R) technology, a proprietary cell encapsulation platform being utilized to develop "targeted" treatments for solid cancerous tumors and insulin dependent diabetes.

Read more...

FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

SILVER SPRING, MD, December 22, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted PharmaCyte Biotech orphan drug designation for its pancreatic cancer treatment. PharmaCyte Biotech's pancreatic cancer treatment combines PharmaCyte Biotech's patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box®, with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials.

Read more...

Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation in New Facility

SILVER SPRING, Md., Dec. 18, 2014 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced that its partner, Austrianova, successfully completed the first live cell encapsulation at Austrianova's new facility in the Thai Science Park in Bangkok, Thailand. This is an important milestone in assuring the facility is compliant with the current Good Manufacturing Practices (cGMP) and that the encapsulation of the cancer prodrug-activating cells used in the Cell-in-a-Box(R) technology platform, as part of PharmaCyte Biotech's pancreatic cancer treatment, will be fully functional.

Read more...

Nuvilex Provides Shareholder Update on Cancer and Diabetes Programs

SILVER SPRING, MD, December 16, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company providing cell solutions for the treatment of diseases, today announced a shareholder update on the Company's cancer and diabetes programs utilizing its Cell-in-a-Box® cellulose-based live cell encapsulation technology.

Read more...

Europe must ‘kick off’ a discussion on changing the pancreatic cancer landscape, says J-Matthias Löhr

Pancreatic cancer is a “medical emergency” and must be treated as such if the situation for patients is to be improved, says J-Matthias Löhr. As professor of gastroenterology and hepatology at Sweden’s Karolinska Institutet, Löhr has direct experience in tackling what has been referred to as the world’s ‘greatest oncological challenge’.

Read more...

Nuvilex Provides Update on Significance of Austrianova's cGMP Live-Cell Encapsulation Facility

SILVER SPRING, Md., Dec. 10, 2014 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, is pleased to provide an update on the significance of its partner, Austrianova, opening a new, state-of-the-art current Good Manufacturing Practices (cGMP)-compliant live-cell encapsulation facility inside the Thailand Science Park (TSP). This facility will produce the Cell-in-a-Box(R) live-cell encapsulation product that will be the centerpiece for all of PharmaCyte Biotech's treatments in human clinical trials.

Read more...